» Authors » Lucie Boyer

Lucie Boyer

Explore the profile of Lucie Boyer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 120
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Boyer L, Robert A, Proulx C, Pineault N
J Immunol Methods . 2008 Feb; 332(1-2):82-91. PMID: 18234208
Expansion of hematopoietic progenitor cells (HPC) ex vivo remains an important focus in fundamental and clinical research. The aim of this study was to determine whether the implementation of such...
12.
Cayer M, Drouin M, Sea S, Forest A, Cote S, Simard C, et al.
J Immunol Methods . 2007 Apr; 322(1-2):118-27. PMID: 17397859
Adenoviral gene transfer into human B lymphocytes and haematopoietic progenitors would allow the characterization of their function on cellular growth, differentiation and survival. Efficient gene expression is however strongly dependent...
13.
Cortin V, Garnier A, Pineault N, Lemieux R, Boyer L, Proulx C
Exp Hematol . 2005 Oct; 33(10):1182-91. PMID: 16219540
Objective: A multi-step statistical strategy was applied to quantify individual and interactive effects of cytokines on megakaryopoiesis and to determine the concentration of the selected cytokines that optimize ex vivo...
14.
Proulx C, Dupuis N, St-Amour I, Boyer L, Lemieux R
Biotechnol Bioeng . 2004 Nov; 88(6):675-80. PMID: 15532059
Based on previous evidence suggesting positive effects of fever on in vivo hematopoiesis, we tested the effect of hyperthermia on megakaryopoiesis (MK) in ex vivo cultures of CD34-enriched cord blood...
15.
Proulx C, Boyer L, Hurnanen D, Lemieux R
J Hematother Stem Cell Res . 2003 Jun; 12(2):179-88. PMID: 12804177
The high proliferative potential of cord blood (CB) stem cells and the identification of the key factor of megakaryopoiesis, thrombopoietin (TPO), permit the ex vivo expansion of megakaryocytes (MKs) for...
16.
Proulx C, Boyer L, St-Amour I, Bazin R, Lemieux R
Transfusion . 2002 Mar; 42(1):59-65. PMID: 11896314
Background: In blood banks, D MoAbs are routinely used to phenotype donors and patients. However, most D MoAbs do not agglutinate RBCs that weakly express D. The use of higher...
17.
Bazin R, Aubin E, Boyer L, St-Amour I, Roberge C, Lemieux R
Blood . 2002 Feb; 99(4):1267-72. PMID: 11830475
The prophylaxis of the hemolytic disease of the newborn requires significant amounts of plasma-derived polyclonal human anti-D. Because of procurement problems, there is a growing interest in replacing plasma-derived anti-D...